IMMX: Immix Biopharma, Inc. - Summary | Jitta

Immix Biopharma, Inc.

NASDAQ:IMMX

Price
$8.72
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (1)
Recent Business Performance (17)
Financial Strength (48)
Return to Shareholders (0)
Competitive Advantage (2)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 36.01% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.21
135.33%
3.06
148.42%
Biotechnology
5.68
35.16%
5.68
35.16%
6.36
42.63%
COMPANY DESCRIPTION
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.